Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.40), $0.02 worse than the analyst estimate of ($1.38). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $11.17 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
- Cintas beats estimates but stock edges lower
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
